This is a knockout-validated antibody summary, based on the publications "Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors", as cited below [1], and "Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas" for western blot knockout validation (figure 2b) [2]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Mouse monoclonal IgG2a, kappa
Company: Abcam
Antibody: SDHB
Catalog number: ab14714
Summary: Mouse monoclonal IgG2a, kappa against purified bovine mitochondrial complex II, with traces of complex III. Reacts with mouse, rat, hamster, cow, human, and zebrafish. Suitable for western blot, immunocytochemistry/immunofluorescence, immunohistochemistry (paraffin and frozen), and flow cytometry.
Western blot
Control and SDHB knockout HCT116 cells. Cells were washed with phosphate buffered saline (PBS) at 4°C and lysed with cell lysis buffer comprising 62.5 mM Tris-HCl (Wako), 10% glycerol (Wako), and 1% sodium dodecyl sulfate (SDS) (Wako).
Block Ace (DS Pharma Biomedical) in PBS containing 0.2% Tween 20 (PBS-T) or Starting Block T20 (PBS) Blocking Buffer (Thermo Scientific).
1:5,000 dilution overnight at 4°C.
Horseradish peroxidase (HRP)-conjugated secondary antibody (eBioscience) for 1 h at room temperature.
ImmunoStar Zeta (Wako) or ImmunoStar LD (Wako). Signals were visualized on an LAS-3000 image analyzer (Fujifilm) and quantified with Multi Gauge Ver. 3.1 (Fujifilm).
The same clone (21A11AE7) is sold as Abcam ab14714; Invitrogen 459230.
- Matlac D, Hadrava Vanova K, Bechmann N, Richter S, Folberth J, Ghayee H, et al. Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. Front Endocrinol (Lausanne). 2021;12:589451 pubmed publisher
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.